Sinusoidal obstruction syndrome (SOS) due to chemotherapy can cause severe hepatotoxicity, leading to impaired outcome in patients with colorectal cancer. A previous study introduced gadoxetic acid-enhanced magnetic resonance imaging (Gd-EOB-MRI) to diagnose SOS.
Purpose
To assess the reproducibility of Gd-EOB-MRI-based SOS diagnosis and its relationship with response to chemotherapy and long-term outcome.
Material and Methods
Twenty-six Gd-EOB-MRI scans of patients undergoing chemotherapy for colorectal liver metastases (CRLM) were retrospectively analyzed. Three radiologists, blinded to clinical data, independently scored presence and severity of SOS on a 5-point scale (0, definitely not present to 4, definitely present). Patients with a score ≥3 were considered SOS+. Inter-observer agreement between readers was assessed with kappa statistics. Response (RECIST 1.1.), occurrence of new CRLM during follow-up (hepatic progression) and overall survival (OS) were compared between patients with and without SOS.
Results
The inter-observer agreement of SOS scores was poor, with quadratic kappas of 0.17–0.40. For the binary outcome of SOS+ (confidence level [CL] 3–4) vs. SOS– (CL 0–2) agreement was poor, with kappas of 0.03–0.37. Median follow-up was 24 months (range 4–44 months). Response and OS between patients with and without SOS did not differ significantly for any of the readers.
Conclusion
Inter-observer agreement for the diagnosis of SOS on Gd-EOB-MRI is poor. No significant correlation with relevant outcomes was found for any of the readers. Therefore, MRI for SOS diagnosis might be less useful than previously reported. Other techniques should be explored to accurately diagnose SOS in absence of histological confirmation.
FerlayJSoerjomataramIDikshitR, et al.
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer2015;
136:E359–386.
2.
van der PoolAEDamhuisRAIjzermansJN, et al.
Trends in incidence, treatment and survival of patients with stage IV colorectal cancer: a population-based series. Colorectal Dis2012;
14:56–61.
3.
SiegelRLMillerKDFedewaSA, et al.
Colorectal cancer statistics, 2017. CA Cancer J Clin2017;
67:177–193.
4.
BrouwerNPMBosALemmensV, et al.
An overview of 25 years of incidence, treatment and outcome of colorectal cancer patients. Int J Cancer2018;
143:2758–2766.
5.
van der GeestLGLam-BoerJKoopmanM, et al.
Nationwide trends in incidence, treatment and survival of colorectal cancer patients with synchronous metastases. Clin Exp Metastasis2015;
32:457–465.
6.
FolprechtGGrotheyAAlbertsS, et al.
Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Onc2005;
16:1311–1319.
7.
NordlingerBSorbyeHGlimeliusB, et al.
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet2008;
371:1007–1016.
8.
LamVWTSpiroCLaurenceJM, et al.
A Systematic Review of Clinical Response and Survival Outcomes of Downsizing Systemic Chemotherapy and Rescue Liver Surgery in Patients with Initially Unresectable Colorectal Liver Metastases. Ann Surg Oncol2012;
19:1292–1301.
HubertCSempouxCHumbletY, et al.
Sinusoidal obstruction syndrome (SOS) related to chemotherapy for colorectal liver metastases: factors predictive of severe SOS lesions and protective effect of bevacizumab. HPB (Oxford)2013;
15:858–864.
11.
RobinsonSMWilsonCHBurtAD, et al.
Chemotherapy-Associated Liver Injury in Patients with Colorectal Liver Metastases: A Systematic Review and Meta-analysis. Ann Surg Oncol2012;
19:4287–4299.
12.
Rubbia-BrandtLAudardVSartorettiP, et al.
Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol2004;
15:460–466.
13.
NakanoHOussoultzoglouERossoE, et al.
Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy.Ann Surg2008;
247:118–124.
14.
MehtaNNRavikumarRColdhamCA, et al.
Effect of preoperative chemotherapy on liver resection for colorectal liver metastases. Eur J Surg Oncol2008;
34:782–786.
15.
Rubbia-BrandtLLauwersGYWangH, et al.
Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis. Histopathology2010;
56:430–439.
16.
BilchikAJPostonGCurleySA, et al.
Neoadjuvant chemotherapy for metastatic colon cancer: a cautionary note. J Clin Oncol2005;
23:9073–9078.
17.
HubertCFervailleCSempouxC, et al.
Prevalence and clinical relevance of pathological hepatic changes occurring after neoadjuvant chemotherapy for colorectal liver metastases. Surgery2010;
147:185–194.
18.
KarouiMPennaCAmin-HashemM, et al.
Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases.Ann Surg2006;
243:1–7.
19.
HubertCSempouxCHorsmansY, et al.
Nodular regenerative hyperplasia: a deleterious consequence of chemotherapy for colorectal liver metastases?Liver Int2007;
27:938–943.
20.
VautheyJNPawlikTMRiberoD, et al.
Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol2006;
24:2065–2072.
21.
MartinsJAlexandrinoHOliveiraR, et al.
Sinusoidal dilation increases the risk of complications in hepatectomy for CRCLM - Protective effect of bevacizumab and diabetes mellitus, serum gamma-glutamyltranspeptidase as predictive factor. Eur J Surg Oncol2016;
42:713–721.
22.
TamandlDKlingerMEipeldauerS, et al.
Sinusoidal obstruction syndrome impairs long-term outcome of colorectal liver metastases treated with resection after neoadjuvant chemotherapy. Ann Surg Oncol2011;
18:421–430.
23.
HubertCLucidiVWeertsJ, et al.
Impact of biological agents on the prevalence of chemotherapy associated liver injury (CALI): Multicentric study of patients operated for colorectal liver metastases. Eur J Surg Oncol2018;
44:1532–1538.
24.
VreulsCPVan Den BroekMAWinstanleyA, et al.
Hepatic sinusoidal obstruction syndrome (SOS) reduces the effect of oxaliplatin in colorectal liver metastases. Histopathology2012;
61:314–318.
25.
ViganoLCapussottiLDe RosaG, et al.
Liver resection for colorectal metastases after chemotherapy: impact of chemotherapy-related liver injuries, pathological tumor response, and micrometastases on long-term survival. Ann Surg2013;
258:731–740; discussion 741–732.
26.
PereyraDRumpfBAmmannM, et al.
The Combination of APRI and ALBI Facilitates Preoperative Risk Stratification for Patients Undergoing Liver Surgery After Neoadjuvant Chemotherapy. Ann Surg Oncol2019;
26:791–799.
27.
SoubraneOBrouquetAZalinskiS, et al.
Predicting high grade lesions of sinusoidal obstruction syndrome related to oxaliplatin-based chemotherapy for colorectal liver metastases: correlation with post-hepatectomy outcome. Ann Surg2010;
251:454–460.
28.
van den BroekMAVreulsCPWinstanleyA, et al.
Hyaluronic acid as a marker of hepatic sinusoidal obstruction syndrome secondary to oxaliplatin-based chemotherapy in patients with colorectal liver metastases. Ann Surg Oncol2013;
20:1462–1469.
29.
OvermanMJMaruDMCharnsangavejC, et al.
Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury. J Clin Oncol2010;
28:2549–2555.
30.
ReimerPSchneiderGSchimaW.Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications. Eur Radiol2004;
14:559–578.
31.
ShinNYKimMJLimJS, et al.
Accuracy of gadoxetic acid-enhanced magnetic resonance imaging for the diagnosis of sinusoidal obstruction syndrome in patients with chemotherapy-treated colorectal liver metastases. Eur Radiol2012;
22:864–871.
32.
EisenhauerEATherassePBogaertsJ, et al.
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer2009;
45:228–247.
33.
FleissJL.Measuring nominal scale agreement among many raters. Psychological Bulletin1971;
76:378–382.
34.
ChoiJHWonYWKimHS, et al.
Oxaliplatin-induced sinusoidal obstruction syndrome mimicking metastatic colon cancer in the liver. Oncol Lett2016;
11:2861–2864.
35.
YouS-HParkBJKimYH.Hepatic Lesions that Mimic Metastasis on Radiological Imaging during Chemotherapy for Gastrointestinal Malignancy: Recent Updates. Korean J Radiol2017;
18:413–426.
36.
CayetSPascoJDujardinF, et al.
Diagnostic performance of contrast-enhanced CT-scan in sinusoidal obstruction syndrome induced by chemotherapy of colorectal liver metastases: Radio-pathological correlation. Eur J Radiol2017;
94:180–190.
37.
ParkSKimHYKimH, et al.
Changes in Noninvasive Liver Fibrosis Indices and Spleen Size During Chemotherapy: Potential Markers for Oxaliplatin-Induced Sinusoidal Obstruction Syndrome. Medicine (Baltimore)2016;
95:e2454.
38.
O’RourkeTRWelshFKTekkisPP, et al.
Accuracy of liver-specific magnetic resonance imaging as a predictor of chemotherapy-associated hepatic cellular injury prior to liver resection. Eur J Surg Oncol2009;
35:1085–1091.
39.
HanNYParkBJKimMJ, et al.
Hepatic parenchymal heterogeneity on contrast-enhanced CT scans following oxaliplatin-based chemotherapy: natural history and association with clinical evidence of sinusoidal obstruction syndrome. Radiology2015;
276:766–774.
